ArticlePakistan journal of medical sciences2026
Diagnostic efficacy of ANAs Combined with serum PTX3 and CCL19 for systemic lupus erythematosus.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the diagnostic efficacy of antinuclear antibody spectrum(ANAs) combined with serum pentraxin 3(PTX3) and chemokine ligand 19(CCL19) for systemic lupus erythematosus (SLE). Methodology: This is a retrospective study. A total of 80 patients with early atypical SLE who presented to the Department of Rheumatology and Immunology of Affiliated Hospital of Hebei University between January 2022 to June 2025 were retrospectively enrolled as the experimental group. Eighty patients with other autoimmune diseases admitted during the same period were assigned to the disease control group, while 60 gender- and age-matched healthy volunteers from the hospital's Physical Examination Center served as the healthy control group. The Western blot assay was utilized to determine the expression of ANAs in serum, whereas the enzyme-linked immunosorbent assay(ELISA) was adopted for quantifying serum PTX3 and CCL19 levels. Results: In the experimental group, complement C3, complement C4, platelet count, white blood cell count, and hemoglobin levels were significantly lower than those in both the healthy control and disease control groups, while serum creatinine and blood urea nitrogen levels were markedly elevated(all Conclusion: ANAs, serum PTX3, and CCL19 can all act as potential diagnostic biomarkers for SLE. The combined detection of these three indicators effectively enhances the diagnostic efficiency of SLE, which is superior to single-marker detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.